Recent Advancements in Vaccinex's ActivMAb® Platform
Vaccinex, Inc. (Nasdaq: VCNX), a pioneering biotechnology company, is taking significant steps in antibody discovery with their innovative ActivMAb® platform. This platform represents a new frontier for treating cancer and neurodegenerative diseases by inhibiting SEMA4D, thereby addressing complex medical challenges in these areas.
Strategic Partnerships and Project Agreements
Recently, Vaccinex announced the signing of various project agreements with notable firms such as Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc, and Incyte. These agreements will leverage the advantages of Vaccinex's technology to develop antibodies against intricate antigen targets. Furthermore, Vaccinex has also formed collaborations with Charles River Labs and OmniAb to assist in their antibody development programs, showcasing the growing recognition of the capabilities of their ActivMAb® technology.
Benefits of ActivMAb® Technology
The ActivMAb® platform stands out for its ability to express complex proteins, such as G-protein-coupled receptors (GPCRs) and ion channels, effectively on poxvirus membranes. This capability is essential for various antibody discovery methods, including antibody-based immunotherapies that use bi-specifics and CAR-T cells. According to Ernest Smith, Chief Scientific Officer at Vaccinex, these capabilities facilitate not only their internal research and development but also the research of their partners.
Insights from Upcoming Presentation
In the forthcoming Society for Immunotherapy of Cancer’s Annual Meeting event, Vaccinex will present their successes in antibody discovery campaigns targeting oncology challenges, highlighting the effectiveness of their ActivMAb® technology.
Event Details
The presentation will occur on November 9, where attendees will have the opportunity to explore the discovery of high-affinity functional antibodies specific for CXCR5, P2X7, and other important multi-pass membrane receptors.
Overview of ActivMAb® and Its Applications
The unique capabilities of the ActivMAb® platform enable critical advancements in detecting and optimizing antibodies specific to complex membrane antigens. It plays a significant role in developing therapeutic drugs against high-value targets that have been difficult to address with conventional small molecule drugs. The platform has already facilitated the progress of the first clinical candidate, CHS-114, which is currently under investigation for cancer treatment.
Vaccinex’s Target Areas
Vaccinex’s leading therapeutic candidate, pepinemab, is designed to block SEMA4D, which is known to cause harmful inflammation in chronic neurological conditions and tumor environments. Pepinemab's ongoing studies continue to show promise for Alzheimer's Disease and other neurodegenerative conditions, with the potential to be a significant player in combination therapies. In oncology, it's being evaluated alongside leading therapies like KEYTRUDA® and BAVENCIO® in advanced clinical trials.
The Future of Vaccinex
As Vaccinex continues to solidify its place among leaders in antibody development, the collaborations they have forged signify a confidence in their technologies and their potential applications. With ongoing studies across various cancer types and neurodegenerative diseases, the company is positioned to make substantial contributions to these therapeutic areas.
Contact with Vaccinex
For further inquiries regarding their research and development process or specific programs, interested parties can reach out to: Elizabeth Evans, PhD, Chief Operating Officer of Vaccinex, Inc. at (585) 271-2700 or via email at eevans@vaccinex.com.
Frequently Asked Questions
What is the ActivMAb® platform?
ActivMAb® is an innovative antibody discovery technology developed by Vaccinex, aimed at targeting complex membrane proteins.
Who are Vaccinex's new partners?
Vaccinex has signed agreements with major firms, including Amgen and Merck, to utilize the ActivMAb® technology for antibody discovery.
What therapeutic areas does Vaccinex target?
Vaccinex focuses on treating cancer and neurodegenerative diseases through innovative therapies like pepinemab.
What is the purpose of the upcoming SITC Annual Meeting?
Vaccinex will share insights on successful antibody discovery campaigns at the upcoming Society for Immunotherapy of Cancer’s meeting.
How can I contact Vaccinex for more information?
Inquiries can be directed to Elizabeth Evans, CO at (585) 271-2700 or via email at eevans@vaccinex.com.
